Core Viewpoint - Wan Yi Medical has submitted its IPO application to the Hong Kong Stock Exchange, aiming to leverage its position as a leading AI-driven solution provider in the medical academic and educational sector in China [1][2]. Company Overview - Wan Yi Medical, established in March 2016, was listed on the New Third Board and later delisted in September 2021. The company focuses on AI-driven solutions to enhance physician development [1]. - The company ranks first in the comprehensive AI solution market for medical academia, education, and research in China, according to Frost & Sullivan [1]. Financial Performance - In 2024, the company reported revenues of approximately RMB 271 million and a net profit of RMB 30 million, with a gross margin of 35.7% [1][4]. - For the first nine months of 2025, revenues reached RMB 191 million, with a net profit of RMB 37 million, marking a year-on-year increase of 100% and a gross margin of 42.27% [1][4]. - The revenue growth from 2024 to 2025 was 7.21%, while the net profit increased by 108.47% during the same period [4]. Product Offerings - The company provides two main AI-driven revenue solutions: 1. A full-process solution for medical academic activities delivered through the MedEvent platform, facilitating workflow coordination and academic exchange among physicians [2]. 2. Digital solutions for medical learning and education, featuring interactive learning suites tailored to physicians' specialties and development goals via the MedAssistant system [2]. Market Position - The market for medical academic, education, and research solutions in China is projected to grow from RMB 668 billion in 2019 to RMB 976 billion in 2024, with a compound annual growth rate (CAGR) of 7.9% [7]. - The AI-driven comprehensive solutions market in this sector is expected to expand from RMB 9 billion in 2019 to RMB 57 billion in 2024, with a CAGR of 45.2% [8]. Competitive Landscape - The market for medical academic and educational solutions in China is highly fragmented, with most companies generating less than RMB 100 million in annual revenue. Wan Yi Medical has established a significant competitive advantage over its peers [9]. - The company leads in key market performance metrics such as revenue, project count, and registered user numbers among AI solution providers in the medical field [12][14]. Management and Governance - The board of directors consists of eight members, including five executive directors and three independent non-executive directors, with a focus on overseeing business strategy and operations [17][18]. - The major shareholder, Ms. Ju Yue, holds a direct stake of 55.25% and controls an additional 15.64% through employee incentive platforms, totaling 72.60% [18].

Company Overview - Wanyiyi Medical has submitted a listing application to the Hong Kong Stock Exchange, with Everbright Securities International as the sole sponsor [1] - The company is positioned as a leading AI-driven solution provider in China, focusing on physician talent development, academic exchange, education, and research outcome transformation [1] Market Position - According to Frost & Sullivan, Wanyiyi Medical ranks first in the comprehensive AI solution market for medical academia, education, and research in China based on comparable revenue for 2024 [1] Core Business - The core business includes two types of AI-driven revenue-generating solutions: a full-process solution for medical academic activities provided through the MedEvent platform, and digital solutions for medical learning and education offered via the MedAssistant system [1] - Wanyiyi Medical has also launched the MedEvidence intelligent tool suite, which includes an AI evidence assistant to support physician-led research processes [1] Market Growth - The market for medical academic, education, and research solutions in China is continuously growing, with the comprehensive AI solution market expected to have a compound annual growth rate (CAGR) of 34.8% from 2024 to 2030, reaching a market size of 33.9 billion RMB by 2030 [1]

Core Viewpoint - Shanghai Wanyi Medical Technology Co., Ltd. (Wanyi Medical) has submitted a listing application to the Hong Kong Stock Exchange, with Everbright Securities International as the exclusive sponsor [1]. Company Overview - Wanyi Medical is a leading AI-driven solution provider in mainland China, focusing on empowering physician talent development. According to Frost & Sullivan, the company ranks first in the comprehensive AI solution market for medical academia, education, and research in mainland China as of 2024 [3]. - The company has developed an ecosystem connecting physicians and various healthcare participants to accelerate the dissemination of medical knowledge, enhance physician education, and promote the application of research outcomes [3]. Product and Service Offerings - The company primarily offers two AI-driven revenue-generating solutions through its intelligent productivity tools: 1. A full-process solution for medical academic activities delivered via the MedEvent platform, aimed at facilitating workflow coordination and academic exchange among physicians. 2. Digital solutions for medical learning and education, featuring an interactive learning suite developed through the MedAssistant system, tailored to physicians' specialties, interests, and development goals [4]. - Wanyi Medical's clients include medical societies/associations, academic organizations, pharmaceutical, and medical device companies. The company delivers solutions on a project-based model [4]. Financial Performance - The company has experienced revenue growth and profitability during the reporting period: - Total revenue increased from RMB 238.8 million in 2023 to RMB 271.1 million in 2024, and from RMB 177.8 million for the nine months ending September 30, 2024, to RMB 190.7 million for the nine months ending September 30, 2025 [6][10]. - Net profit figures for the same periods were RMB 29.9 million, RMB 29.7 million, RMB 17.7 million, and RMB 36.9 million, respectively [6]. - The company's profit margins were 12.5%, 11.0%, 9.9%, and 19.3% for the years 2023, 2024, and the nine-month periods ending September 30 for 2024 and 2025 [6]. Shareholder Structure - According to the prospectus, Ms. Ju Yue is the controlling shareholder due to her direct interests in the company and her control over the employee incentive platform [7].

Core Viewpoint - Shanghai Wanyi Medical Technology Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with Everbright Securities International as its sole sponsor [1]. Company Overview - Wanyi Medical is a leading AI-driven solution provider in China, focused on empowering physician talent development. It ranks first in the comprehensive AI solution market for medical academia, education, and research in China, according to Frost & Sullivan [4]. - The company has developed an ecosystem connecting physicians and various healthcare participants to accelerate the dissemination of medical knowledge, enhance physician education, and promote the application of research outcomes [4]. - Wanyi Medical offers two main AI-driven revenue-generating solutions: (i) a full-process solution for medical academic activities delivered through the MedEvent platform, and (ii) digital solutions for medical learning and education featuring interactive learning kits tailored to physicians' specialties, interests, and development goals [4]. - The company has launched MedEvidence, a suite of intelligent tools including an AI evidence-based assistant to support end-to-end physician-led research processes, enhancing product functionality and physician engagement [4]. Financial Information - For the fiscal years ending September 30, 2023, 2024, and 2025, the company reported revenues of approximately RMB 239 million, RMB 271 million, and RMB 191 million, respectively [5]. - The annual profits for the same periods were approximately RMB 29.87 million, RMB 29.72 million, and RMB 36.88 million [6]. - The gross profit margins for the fiscal years were recorded at 37.9%, 35.7%, and 42.3% [8]. Market Insights - The market for medical academic, education, and research solutions in China is projected to grow from RMB 66.8 billion in 2019 to RMB 97.6 billion in 2024, with a compound annual growth rate (CAGR) of 7.9%. By 2030, the market size is expected to reach RMB 179.5 billion, with a CAGR of 10.7% from 2024 to 2030 [10]. - The market for comprehensive AI solutions in medical academia, education, and research is expected to grow from RMB 0.9 billion in 2019 to RMB 5.7 billion in 2024, with a CAGR of 45.2%. By 2030, the market is projected to reach RMB 33.9 billion, with a CAGR of 34.8% from 2024 to 2030 [13].

的申請版本 警 告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）與證券及期貨事務監察委員會（「證監會」）的要求而刊發， 僅用作提供資訊予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即代表 閣下知悉、 接納並向本公司、其保薦人、聯席整體協調人、顧問或包銷團成員表示同意： 本公司招股章程根據香港法例第32章《公 司（清 盤 及 雜 項 條 文）條 例》與 香 港 公 司 註 冊 處 處 長 登 記 前，本 公 司 不 會 向 香 港 公 眾 人 士 提 出 要 約 或 邀 請。倘 於 適 當 時 候 向 香 港 公 眾 人 士 提 出 要 約 或 邀 請，準 投 資 者 務 請 僅 依 據 呈 交 香 港 公 司 註 冊 處 登 記 的 本 公 司 招 股 章 程 作 出 投 資 決 定；有 關 文 本 將 於 發 售 期 內 向 公 眾 刊 發。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的；投資者不應根據本文件中的資料 作出任何投資決定； (b) 在聯交所網站登載本文件或其補充、修訂或更換附頁，並不引起本公司、其任何保薦人 ...